These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 815983)

  • 1. [Reaction of the Trypanosoma cruzi strain to the experimental therapeutical response to Bay 2502 (results of long term treatment)].
    Andrade SG; Figueira RM; Carvalho ML; Gorini DF
    Rev Inst Med Trop Sao Paulo; 1975; 17(6):380-9. PubMed ID: 815983
    [No Abstract]   [Full Text] [Related]  

  • 2. Animal experimental investigation into the activity of nifurtimox against Trypanosoma cruzi.
    Haberkorn A; Gönnert R
    Arzneimittelforschung; 1972 Sep; 22(9):1570-82. PubMed ID: 4630483
    [No Abstract]   [Full Text] [Related]  

  • 3. [Experimental study on the therapeutic action of Ro 7-1051 on infections caused by different strains of Trypanosoma cruzi].
    Andrade SG; Figueira RM
    Rev Inst Med Trop Sao Paulo; 1977; 19(5):335-41. PubMed ID: 416483
    [No Abstract]   [Full Text] [Related]  

  • 4. [Experimental study on the resistance of a strain of Trypanosoma cruzi to Bay 2502].
    Andrade SG; Andrade ZA; Figueira RM
    Rev Inst Med Trop Sao Paulo; 1977; 19(2):124-9. PubMed ID: 408896
    [No Abstract]   [Full Text] [Related]  

  • 5. [Etiological treatment of Chagas' disease].
    Rassi A
    Arq Bras Cardiol; 1982 Apr; 38(4):277-81. PubMed ID: 6820273
    [No Abstract]   [Full Text] [Related]  

  • 6. Differences in the susceptibility of Trypanosoma cruzi strains to active chemotherapeutic agents.
    Brener Z; Costa CA; Chiari C
    Rev Inst Med Trop Sao Paulo; 1976; 18(6):450-5. PubMed ID: 828295
    [No Abstract]   [Full Text] [Related]  

  • 7. Trypanosoma cruzi: acute and long-term infection in the vertebrate host can modify the response to benznidazole.
    Caldas S; Santos FM; de Lana M; Diniz LF; Machado-Coelho GL; Veloso VM; Bahia MT
    Exp Parasitol; 2008 Mar; 118(3):315-23. PubMed ID: 17945216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment of Chagas' disease].
    Apt W
    Rev Med Chil; 1985 Feb; 113(2):162-6. PubMed ID: 3936147
    [No Abstract]   [Full Text] [Related]  

  • 9. [Etiologic therapy of Chagas' disease].
    Boainain E; Rassi A
    Arq Bras Cardiol; 1979 Jun; 32(6):395-9. PubMed ID: 116629
    [No Abstract]   [Full Text] [Related]  

  • 10. The urgent need to develop new drugs and tools for the treatment of Chagas disease.
    Muñoz MJ; Murcia L; Segovia M
    Expert Rev Anti Infect Ther; 2011 Jan; 9(1):5-7. PubMed ID: 21171870
    [No Abstract]   [Full Text] [Related]  

  • 11. The structure-activity relationship of 4-(5'-nitrofurfurylidene-amino)-tetrahydro-4H-1,4-thiazine-1,1-dioxides active against Trypanosoma cruzi.
    Bock M; Haberkorn A; Herlinger H; Mayer KH; Petersen S
    Arzneimittelforschung; 1972 Sep; 22(9):1564-9. PubMed ID: 4630482
    [No Abstract]   [Full Text] [Related]  

  • 12. 5-Nitro-2-furyl derivative actives against Trypanosoma cruzi: preliminary in vivo studies.
    Cabrera E; Murguiondo MG; Arias MG; Arredondo C; Pintos C; Aguirre G; Fernández M; Basmadjián Y; Rosa R; Pacheco JP; Raymondo S; Di Maio R; González M; Cerecetto H
    Eur J Med Chem; 2009 Oct; 44(10):3909-14. PubMed ID: 19446929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suppression of antibody dependent cytotoxicity to Trypanosoma cruzi in chronic chagasic mice after treatment with nifurtimox.
    Chambó JG; Cabeza Meckert PM; Laguens RP
    Medicina (B Aires); 1988; 48(1):49-53. PubMed ID: 3146009
    [No Abstract]   [Full Text] [Related]  

  • 14. [Isoenzymatic pattern of Trypanosoma cruzi Y strain after specific chemotherapy].
    Silva RC; Santiago CM; Pontes AL; Andrade SG
    Mem Inst Oswaldo Cruz; 1989; 84(1):81-6. PubMed ID: 2108307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trypanosoma cruzi: nifurtimox's effect on infectivity.
    Cardoni RL; Rimoldi MT; de Bracco MM
    Exp Parasitol; 1977 Dec; 43(2):370-5. PubMed ID: 413732
    [No Abstract]   [Full Text] [Related]  

  • 16. Trypanosoma cruzi: dehydroepiandrosterone (DHEA) and immune response during the chronic phase of the experimental Chagas' disease.
    Caetano LC; Santello FH; Del Vecchio Filipin M; Brazão V; Caetano LN; Toldo MP; Caldeira JC; do Prado Júnior JC
    Vet Parasitol; 2009 Jul; 163(1-2):27-32. PubMed ID: 19446400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thioridazine treatment modifies the evolution of Trypanosoma cruzi infection in mice.
    Rivarola HW; Fernández AR; Enders JE; Fretes R; Gea S; Suligoy M; Palma JA; Paglini-Oliva P
    Ann Trop Med Parasitol; 1999 Oct; 93(7):695-702. PubMed ID: 10715697
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ultrastructural observations on the activity of nifurtimox on the causative organism of Chagas' disease. I. Trypanosoma cruzi in tissue cultures.
    Voigt WH; Bock M; Gönnert R
    Arzneimittelforschung; 1972 Sep; 22(9):1586-9. PubMed ID: 4567081
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of length of treatment with Bayer 2502 on isolation of Trypanosoma cruzi and resistance to challenge in the mouse.
    Morrow DT; Wescott RB; Davis WC
    Am J Trop Med Hyg; 1977 May; 26(3):382-6. PubMed ID: 405877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trypanosoma cruzi: Induction of benznidazole resistance in vivo and its modulation by in vitro culturing and mice infection.
    Dos Santos FM; Caldas S; de Assis Cáu SB; Crepalde GP; de Lana M; Machado-Coelho GL; Veloso VM; Bahia MT
    Exp Parasitol; 2008 Dec; 120(4):385-90. PubMed ID: 18823980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.